Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Oklahoma
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
EMD Serono
ImmunityBio, Inc.
University Health Network, Toronto
EMD Serono
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Exelixis